BRUKINSA®▼ as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).1
The efficacy of BRUKINSA in the treatment of CLL has been demonstrated both as first-line treatment, and for relapsed/refractory CLL with clinical benefit observed across major CLL subtypes.1–4
BRUKINSA demonstrated superior efficacy and safety compared with ibrutinib, the first-generation BTK inhibitor, in patients with relapsed/refractory CLL.3,4
BRUKINSA has a favourable safety and tolerability profile.1–4 A lower incidence of treatment discontinuation for any reason was observed with BRUKINSA compared with ibrutinib, including adverse events, cardiac events and progressive disease.3,4
The use of BRUKINSA as monotherapy for the treatment of adult patients with CLL is supported by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the Health Service Executive (HSE) in Ireland.5–7